Exact Mass: 462.0951
Exact Mass Matches: 462.0951
Found 36 metabolites which its exact mass value is equals to given mass value 462.0951,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
2-Ethoxy-3-[4-[2-[4-(trifluoromethylsulfonyloxy)phenyl]ethoxy]phenyl]propanoic acid
2-Ethoxy-3-[4-[2-[4-(trifluoromethylsulphonyloxy)phenyl]ethoxy]phenyl]propanoic acid
di(propan-2-yl)-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane
di(propan-2-yl)-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane
n-[(3-trimethoxysilyl)propyl]ethylenediamine triacetic acid trisodium salt
n-[(3-trimethoxysilyl)propyl]ethylenediamine triacetic acid trisodium salt
Eletriptan HBr
Eletriptan hydrobromide
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Eletriptan hydrobromide (Eletriptan HBr) is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively.
Rintodestrant
Rintodestrant
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2116 - Selective Estrogen Receptor Down Regulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
[4-[(Z)-[3-(2-aminoethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-2-methoxyphenyl] 2,5-dimethylbenzenesulfonate
[4-[(Z)-[3-(2-aminoethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-2-methoxyphenyl] 2,5-dimethylbenzenesulfonate
7-(3,4-Dihydroxyphenyl)-4-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one
7-(3,4-Dihydroxyphenyl)-4-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one
3-L-aspartyl-AMP
3-L-aspartyl-AMP
An L-aspartic acid derivative that is the ester obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the 3-hydroxy group of AMP.
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide
2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose
2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose
(2S)-2-[[2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid
(2S)-2-[[2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid
MDM2-IN-1
MDM2-IN-1
MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration[1].
4,12-bis(but-2-en-2-yl)-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
4,12-bis(but-2-en-2-yl)-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
2'-(3,4-dihydroxyphenyl)-6'-[2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione
2'-(3,4-dihydroxyphenyl)-6'-[2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione
{8,11-dihydroxy-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid
{8,11-dihydroxy-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid
3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one
3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one
4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione
4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione
(6ar,9r,9as)-9-acetyl-5-bromo-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-6a-methyl-1h,9h,9ah,9bh-furo[2,3-h]isochromene-6,8-dione
(6ar,9r,9as)-9-acetyl-5-bromo-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-6a-methyl-1h,9h,9ah,9bh-furo[2,3-h]isochromene-6,8-dione
(2s,2's)-2'-(3,4-dihydroxyphenyl)-6'-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione
(2s,2's)-2'-(3,4-dihydroxyphenyl)-6'-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione
4,12-bis[(2e)-but-2-en-2-yl]-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
4,12-bis[(2e)-but-2-en-2-yl]-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
{8,11-dihydroxy-2-[(2s,3s)-2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid
{8,11-dihydroxy-2-[(2s,3s)-2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid
(2r,2'r,3s,3'r,3'ar)-3'-hydroxy-5'-methyl-3,3'a-bis(methylsulfanyl)-3h,3'h-dispiro[1-benzofuran-2,6'-[1,2]oxazolo[2,3-a]pyrazine-2',1''-cyclohexan]-3''-ene-2'',4',7'-trione
(2r,2'r,3s,3'r,3'ar)-3'-hydroxy-5'-methyl-3,3'a-bis(methylsulfanyl)-3h,3'h-dispiro[1-benzofuran-2,6'-[1,2]oxazolo[2,3-a]pyrazine-2',1''-cyclohexan]-3''-ene-2'',4',7'-trione
(1s,4r,6r,14e,17e)-4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione
(1s,4r,6r,14e,17e)-4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione
3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one
3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one
